Concert Pharmaceuticals Reports Second Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Concert Pharma (CNCE) Reports Q2 EPS of $0.16
August 5, 2021 7:55 AM EDTConcert Pharma (NASDAQ: CNCE) reported Q2 EPS of $0.16, versus ($0.41) reported last year. Revenue for the quarter came in at $32 million, versus $6.4 million reported last year.
For earnings history and earnings-related data on Concert Pharma (CNCE) click here.
... More